PFIZER INC Share-based Payment Arrangement, Expense, Tax Benefit
PFIZER INC (PFE) reported Share-based Payment Arrangement, Expense, Tax Benefit of $140.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-02-26
- PFIZER INC share-based payment arrangement, expense, tax benefit for fiscal 2025 was $140.00M, a 15.15% decline from fiscal 2024.
- PFIZER INC share-based payment arrangement, expense, tax benefit for fiscal 2024 was $165.00M, a 77.42% increase from fiscal 2023.
- PFIZER INC share-based payment arrangement, expense, tax benefit for fiscal 2023 was $93.00M, a 41.87% decline from fiscal 2022.
- PFIZER INC share-based payment arrangement, expense, tax benefit for fiscal 2022 was $160.00M, a 29.52% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|
| 2025-12-31 | $140.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $165.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $93.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $160.00M 10-K · filed 2025-02-27 |
| 2021-12-31 | $227.00M 10-K · filed 2024-02-22 |
| 2020-12-31 | $141.00M 10-K · filed 2023-02-23 |
| 2019-12-31 | $137.00M 10-K · filed 2022-02-24 |
| 2018-12-31 | $180.00M 10-K · filed 2021-02-25 |
| 2013-12-31 | $173.00M 10-K · filed 2014-02-28 |
| 2012-12-31 | $149.00M 10-K · filed 2014-02-28 |
| 2011-12-31 | $139.00M 10-K · filed 2014-02-28 |
| 2010-12-31 | $129.00M 10-K · filed 2013-02-28 |
| 2009-12-31 | $99.00M 10-K · filed 2012-02-28 |
| 2008-12-31 | $114.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |